Forgot Password?
Return to Course Listing

CME: Asthma and allergic asthma: personalizing treatment to the patient and therapeutic updates

Activity Description / Statement of Need:

In this online CME self-learning program:

 

Asthma is a common disorder of the airways that is complex and characterized by variable and recurring symptoms, airflow obstruction, bronchial hyper-responsiveness, and an underlying inflammation, and it affects 23 to 25 million people in the United States including 7 million children. The prevalence of asthma has increased significantly during the past decades in the United States. Development of asthma and its attendant symptoms may be related to any number of factors, including innate immunity, family history and genetics, and degree of environmental allergen exposure. Common triggers include: allergen-induced, asthma induced by aspirin and other nonsteroidal anti-inflammatory drugs, atopic dermatitis, stress, and exercise. In aggregate, the annual costs attributed to asthma in the U.S. are between $18 and $56 billion.

 

There are several barriers to appropriate self-management of asthma. A large gap in care that could be remedied by continuing education programming is poor patient education. A patient’s lack of understanding of the disorder, monitoring parameters, and its treatment management is a significant barrier; as a result, they may under- or over-treat. Failure to follow a treatment plan and poor administration of rescue bronchodilators inhalers can lead to needless increase in cost in asthma management. The Centers for Disease Control and Prevention estimates that less half of asthma patients have been taught to avoid triggers, and of those who have been educated, less than half fail to adhere to the clinical education they have received. One group of researchers concluded that “it is likely that asthma disparities can be improved, in part, by improving patient/provider communication,” underscoring the potential that remains for healthcare professionals to continue bridging these remaining gaps and justifying continuing education programming.

 

Agenda

 

Introduction, Disclosures

Definition and epidemiology of and risk factors for asthma and allergic asthma

•          Statistics – snapshots and trends

•          Racial/ethnic disparities

Clinical features and pathophysiology of asthma and allergic asthma: a brief review

•          The common pathophysiology: airway remodeling, inflammation, and hyper-responsiveness

•          Onset, pediatric vs. adult

•          Comorbidities and risk factors

•          Severity

•          Allergic asthma vs. non-

•          Updates in treatment: updates in the medical literature and emerging therapies

•          Brief review of guidelines the role of corticosteroids including the role of small particle/molecule formulations

•          The role of long-acting beta-2 agonists and their related FDA warnings and guidance

•          Next steps: difficult-to-control cases

•          Immunotherapy in allergic asthma

•          Evolution in care: emerging therapies on the horizon

•          Best practice: putting it all together

Personalizing care: barriers to therapy

•          Race and ethnicity

•          Socioeconomic status, geographical setting, and access to care

•          Strategies to address above barriers

Personalizing care: review of best practices in patient education

•          Root causes of non-adherence

•          Technology and techniques for improving adherence

•          The emphasis on technique; spacer devices and beyond

•          Tracking outcomes: success and less

Summary

Target Audience:

Healthcare professionals including: allergists, pulmonologists, immunologists, primary care physicians, and any other healthcare professionals who commonly come into clinical contact with patients with asthma.


This program is supported by an educational grants from Novartis, Sunovion Pharmaceuticals, and MEDA Pharmaceuticals.


Release Date: July 01, 2014 -- Expiration Date: July 01, 2016

Faculty: Stanley Schwartz,

Agenda

Learning Objectives

By the end of the session the participant will be able to:

  • 1. Describe the pathophysiology and clinical features of allergic asthma.
  • 2. Apply existing diagnostic recommendations, criteria, and screening tools to practice in the management of asthma.
  • 3. Formulate an effective stepwise approach to treating patients with asthma based on the severity and etiology of their disease in a manner that: optimizes pharmacotherapy; employs medical devices where appropriate; and promotes adherence to therapy.
  • 4. Apprise fellow healthcare professionals of changes to the literature since the last major guideline release.
  • 5. Formulate strategies to combat barriers to care, taking into account: demographic and socioeconomic factors and appropriate use/technique of medication administration.

Accreditation

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.


Faculty Disclosure and Resolution of COI

 As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

 

Faculty Disclosures:  

 

Stanley Schwartz, MD, PhD is a shareholder of Pfizer and Merck.

 

Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.

 

Commercial Support Disclosure: This program is supported by an educational grants from Novartis, Sunovion Pharmaceuticals, and MEDA Pharmaceuticals.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

This activity has expired so no certificate is available.